Fenofibrate Starting Dose
For patients with normal renal function (eGFR ≥60 mL/min/1.73 m²), start fenofibrate at 160 mg once daily for primary hypercholesterolemia or mixed dyslipidemia, or 54-160 mg daily for severe hypertriglyceridemia, with dosing individualized based on triglyceride severity. 1
Formulation-Specific Dosing
The FDA-approved fenofibrate tablet formulation uses the following starting doses 1:
- Primary hypercholesterolemia or mixed dyslipidemia: 160 mg once daily
- Severe hypertriglyceridemia: 54-160 mg once daily (adjust based on lipid response at 4-8 week intervals)
- Maximum dose: 160 mg once daily
Critical administration requirement: Fenofibrate tablets must be taken with meals to optimize bioavailability 1.
Note that the suprabioavailable tablet formulation (54 mg and 160 mg) achieves equivalent plasma concentrations to the older micronized capsules (67 mg and 200 mg, respectively) at lower doses 2.
Renal Function Adjustments
Renal dosing is mandatory and must be assessed before initiating therapy 3:
eGFR-Based Dosing Algorithm:
- eGFR ≥60 mL/min/1.73 m²: Standard dosing (54-160 mg daily)
- eGFR 30-59 mL/min/1.73 m²:
- eGFR <30 mL/min/1.73 m²: Contraindicated - do not use 3, 1
The ACC/AHA guidelines provide Class I, Level B evidence that renal status must be evaluated before fenofibrate initiation, within 3 months after starting, and every 6 months thereafter using both serum creatinine and eGFR 3. This is critical because fenofibrate causes acute reductions in eGFR 4 and increases serum creatinine levels even in healthy individuals 5.
Monitoring Requirements
Baseline assessment before starting fenofibrate 3:
- Serum creatinine and calculated eGFR
- Fasting lipid panel
- Hepatic transaminases
Follow-up monitoring:
- Renal function: Within 3 months, then every 6 months 3
- Lipid panel: 4-8 weeks after initiation, then periodically 1
- If eGFR persistently decreases to <30 mL/min/1.73 m², discontinue fenofibrate immediately 3
Critical Safety Considerations
Elderly Patients
Dose selection must be based on renal function, as elderly patients frequently have reduced creatinine clearance 1. Calculate eGFR before prescribing, as age-related renal impairment may not be apparent from serum creatinine alone 6.
Combination with Statins
- Never combine fenofibrate with gemfibrozil - this increases rhabdomyolysis risk significantly 3
- Fenofibrate may be considered with low- or moderate-intensity statins only if benefits outweigh risks 3
- Monitor for muscle symptoms, as fenofibrate-associated rhabdomyolysis can present without classic myalgia or dark urine 6
Common Pitfall
The most frequent error is failing to adjust the dose for mild-moderate renal impairment (eGFR 30-59). Many clinicians miss that the maximum dose in this population is 54 mg daily, not 160 mg 3, 1. Starting at full dose in patients with eGFR 30-59 significantly increases the risk of renal deterioration and rhabdomyolysis 7, 6.
Contraindications
Do not use fenofibrate in patients with 1:
- Severe renal impairment (eGFR <30 mL/min/1.73 m²)
- Active liver disease
- Preexisting gallbladder disease
- Known hypersensitivity to fenofibrate